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Abstract
Background and Purpose The results of a large prospective randomized trial have shown the eﬃcacy of oral anticoagulation in
the secondary prevention of major vascular events in patients with nonrheumatic atrial ﬁbrillation (NRAF); less well established
is the role of antiplatelet agents. The present study compared the eﬀects of indobufen, a reversible inhibitor of platelet
cyclooxygenase, with those of warfarin in this setting.
Methods A total of 916 patients with NRAF and a recent (≤15 days) cerebral ischemic episode were admitted to this
multicenter, randomized study, during which they were treated with either indobufen (100 or 200 mg BID) or warfarin (to obtain
an international normalized ratio of 2.0 to 3.5) for 12 months. The two groups (462 on indobufen and 454 on warfarin) were well
balanced in terms of their main baseline characteristics. The primary outcome of the study was the combined incidence of
nonfatal stroke (including intracerebral bleeding), pulmonary or systemic embolism, nonfatal myocardial infarction, and vascular
death.
Results At the end of follow-up, the incidence of primary outcome events was 10.6% in the indobufen group (95% conﬁdence
interval, 7.7% to 13.5%) and 9.0% in the warfarin group (95% conﬁdence interval, 6.3% to 11.8%), with no statistically
signiﬁcant diﬀerence between treatments. The frequency of noncerebral major bleeding complications was low: only four cases
(0.9%) of gastrointestinal bleeding were observed, all of them in the warfarin group.
Conclusions We conclude that, within the limitations of its design, this study may help the medical community in devising
appropriate antithrombotic strategies for NRAF patients for whom oral anticoagulants are contraindicated or do not represent a
feasible approach to treatment.
antiplatelet therapy atrial ﬁbrillation thromboembolism warfarin
Ischemic stroke is due to cardiogenic embolism in approximately 15% of cases,  and NRAF is the most common cardiac
disease associated with cerebral embolism.  A 10% to 20% incidence of stroke recurrence has been reported during the year
after a ﬁrst ischemic episode in patients with NRAF, with some studies describing a recurrence rate of up to 15% during the
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ﬁrst month.   The value of antithrombotic therapy in the secondary prevention of thromboembolic events in such patients has
been examined by the placebo-controlled EAFT,  in which oral anticoagulant treatment (INR, 2.5 to 4.0) reduced the risk of
stroke and major vascular events by approximately 70% and 50%, respectively. However, this clear-cut beneﬁt was associated
with a greater risk of major hemorrhagic events. In the same study, aspirin (300 mg/d) led to a nonsigniﬁcant 20% reduction in
the risk of important vascular events,  suggesting that antiplatelet prophylaxis may not be as eﬀective as oral anticoagulation.
Consequently, the search for a safer and eﬀective alternative to oral anticoagulation is still ongoing.
Indobufen is a reversible inhibitor of platelet cyclooxygenase activity,    which has been shown to be eﬀective as an
antithrombotic agent in the prevention of graft occlusion after coronary artery bypass surgery    as well as in the prevention
of thromboembolic events in heart disease patients at risk of embolism.  The present study was designed to compare the
eﬃcacy and safety of indobufen and of warfarin in the prevention of major vascular events in NRAF patients who had
experienced a recent cerebral ischemic episode.
Subjects and Methods
Patient Selection
SIFA was a prospective, randomized, open study involving 80 Italian centers. The eligible patients were subjects of either sex
older than 30 years with chronic or paroxysmal NRAF, who had had a transient ischemic attack or ischemic stroke in the
previous 2 weeks. At least two ECGs documenting stable AF during the 3 weeks before study entry were required for the
diagnosis of chronic AF; intermittent AF had to be documented by means of ECGs and/or Holter monitoring recordings
showing sinus rhythm between at least two episodes of AF during the preceding 12 months.
The qualifying event for admission to the study was the occurrence of a cerebrovascular ischemic episode no more than 15
days before study entry (with no evidence of hemorrhage on CT), classiﬁed as follows: (1) nondisabling stroke, eg, focal
neurological deﬁcit for more than 24 hours leading to a disability of grade 3 or less on the modiﬁed Rankin scale, or (2)
transient ischemic attack, with a nonevolutive course lasting less than 24 hours.
Patients were excluded if they had rheumatic AF or if they had undergone cardioversion during the 2 weeks preceding the
qualifying event. Other cardiac reasons for exclusion were echocardiographic evidence of intracardiac thrombosis or tumor; left
ventricular aneurysm, severe congestive heart failure (New York Heart Association functional class >3), or the presence of
prosthetic valves; acute myocardial infarction or unstable angina during the previous month; carotid endarterectomy or
coronary or peripheral revascularization procedures performed during the previous 6 months; severe arterial hypertension
poorly controlled by drugs; and acquired or congenital valvular disease (except mitral valve prolapse or mitral annulus
calciﬁcation). The neurological exclusion criteria included CT brain scan evidence of cerebral hemorrhage, documented
arteriovenous malformation or tumor, severe involutive cerebral disease, or the presence of a carotid lesion requiring surgical
intervention. Other reasons for exclusion included the need for chronic anticoagulant therapy, contraindication to the study
drugs, severe renal or hepatic insuﬃciency, a life expectancy of less than 12 months because of other medical conditions, or
the patient’s refusal to participate.
Each patient was required to give informed consent after receiving adequate information about the meaning of randomization,
the intended treatment, and the estimated risk-beneﬁt ratio. Moreover, to improve compliance since the assigned treatment
was to be continued at home, each patient’s attending physician was informed of the type of treatment being given, its
duration, and the examinations to be performed during follow-up.
The study protocol was approved by the ethics committees of the participating centers.
Treatment
The patients were assigned to one of the treatments by means of a blocked randomization procedure stratiﬁed by center, with
blocks of four patients (two assigned to each treatment) being used to ensure a good balance between treatments even in
small recruiting centers. The treatment (indobufen or warfarin) was assigned centrally by telephone through a randomization
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service in Milan. Indobufen was administered orally at the recommended dose of 200 mg BID, which was lowered to 100 mg
BID in patients with impaired renal function (creatinine clearance <80 mL/min). Anticoagulant treatment with warfarin was
adjusted to ensure INR values within the range of 2.0 to 3.5. Throughout the study period, no drugs were permitted that would
aﬀect platelet aggregation or blood coagulation or that might interfere with the action of the study drugs. The planned duration
of treatment was 12 months. The physician in charge at each center was free to discontinue treatment whenever the
occurrence of a severe adverse event or of a concomitant disease made this necessary.
Assessments
Baseline
At entry, each patient’s medical history was taken and he/she underwent a physical examination. The clinical characteristics of
the qualifying cerebral event (type, location, duration of symptoms, and vascular territory involved) were recorded, together
with the patient’s demographic data, vascular risk factors, cardiac history and status, and neurological history. The following
diagnostic procedures were also performed: routine blood laboratory tests, baseline 12-lead ECG, M-mode and two-
dimensional echocardiography, duplex ultrasonography of the supra-aortic trunks, CT brain scan, and chest roentgenography.
Follow-up
Every 3 months, each patient underwent a clinical examination, ECG, and laboratory tests (INR), and a record was made of the
occurrence of any outcome events, the degree of disability, the appearance of any adverse drug reactions, and the patient’s
compliance with the prescribed drugs. All deaths and their causes were recorded, with death certiﬁcates being obtained in the
case of deaths occurring outside the hospital. The times and reasons for all patient withdrawals were identiﬁed. Study
medication was withdrawn when an end point occurred or when the patient experienced a major hemorrhage.
Outcome Events
The study was planned to test the eﬀect of the two treatments in the prevention of any major vascular event regardless of its
origin, since we thought that this approach would have more value in everyday clinical practice.
Therefore, the combined incidence of the following vascular events was considered the primary outcome of the study: nonfatal
stroke (including intracranial bleeding), nonfatal myocardial infarction, systemic or pulmonary embolism, and vascular death.
CT-documented ischemic or hemorrhagic stroke was deﬁned as the sudden onset of a focal neurological deﬁcit lasting for
more than 24 hours. The stroke was classiﬁed as major if the patient’s Rankin classiﬁcation disability score was greater than 3
four weeks after the acute onset.
A diagnosis of myocardial infarction required at least two of the following criteria: history of chest discomfort, development of a
pathological Q wave on ECG tracings, and elevation of speciﬁc cardiac enzymes to values of more than twice the upper normal
limit.
Systemic embolism was deﬁned as acute ischemia of the limbs or internal organs, associated with clinical or radiological
evidence of arterial occlusion, without any severe atherosclerotic vascular disease. In the case of pulmonary embolism, lung
perfusion scintigraphy was required. Vascular death included fatal stroke, fatal myocardial infarction, sudden death (occurring
within 1 hour of the onset of symptoms), and death due to heart failure, systemic or pulmonary embolism, noncerebral
hemorrhagic events, or other vascular causes.
If a patient died within 4 weeks of a major event, this was recorded as fatal. All of the outcome events were independently
classiﬁed by three members of the Steering Committee who were unaware of the treatment allocation. The ﬁnal judgment was
based on the consensus of at least two members, who reviewed, in a blinded fashion, original medical records. If consensus
was not reached, the case was submitted to the Steering Committee.
Hemorrhagic Events
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Noncerebral and nonfatal bleeding events were classiﬁed as major if they were severe, ie, they made it necessary to hospitalize
the patient, administer a blood transfusion, or perform surgery. All other hemorrhagic events were classiﬁed as minor.
Statistical Methods
Sample Size
SIFA was a prospective, randomized, open clinical trial planned to test the equivalence of the eﬀects of antiaggregant and
anticoagulant treatments. Since the absolute equivalence of two treatments can never be demonstrated, we chose to indicate
a prespeciﬁed diﬀerence below which the two treatments could be deﬁned as equivalent.
On the basis of the results of previous studies, it was assumed that the proportion of successes (ie, the probability of remaining
free of one of the events considered a primary end point during the ﬁrst year of follow-up) would be 0.86 in the warfarin group.
The sample size was calculated in such a way as to exclude the possibility that the diﬀerence in the success rate between the
warfarin and indobufen groups exceeded 0.06. The power (1−β) was set at 90% and the α level at 0.10. In studies of treatment
equivalence, α can be safely set at a high level (10% or 20%), since the wrong conclusion of ﬁnding a diﬀerence when this
does not exist would not be a serious mistake because its clinical implications would be to keep patients on the standard
treatment. The sample size was calculated for a one-sided test, which is customary when the objective is to ensure that the
new agent is not inferior to the standard treatment. On the basis of these assumptions, the required sample size was 880
patients (440 per group).
Analysis
The statistical methods used in the univariate analyses included t tests for the diﬀerences between mean values, χ  tests for
the comparison of proportions, and hazard ratios (relative risks) to measure the associations between outcomes and
variables.  Probability of remaining free of events was estimated by the Kaplan-Meier method,  and cumulative event-free
survival was compared between treatments with the log-rank test. The multivariate analyses made to control for potential
confounders and prognostic factors were performed with the Cox proportional hazard model.  
The equivalence of the treatments on the basis of the assumptions described above was tested by means of the appropriate χ
test.   All of the statistical evaluations were performed with both intention-to-treat and on-treatment analyses.
The on-treatment analysis included all of the primary end points occurring during the course of drug administration or within 15
days of drug discontinuation.
Results
Baseline Patient Characteristics
A total of 916 patients were admitted to the study: 462 in the indobufen and 454 in the warfarin group. The baseline
characteristics of the patients are given in Table 1 . Approximately two thirds of the patients were older than 70 years, and
there was a slightly higher prevalence of women. The two groups were comparable in terms of the qualifying cerebral ischemic
event, type of AF, prevalence of vascular risk factors, presence and degree of heart failure, echocardiographic parameters, and
CT scan and supra-aortic trunk ultrasound ﬁndings.
Table 1.
Baseline Characteristics of 916 Patients With NRAF and a Recent Cerebral Ischemic Episode
Indobufen (n=462) Warfarin (n=454)
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Indobufen (n=462) Warfarin (n=454)
Men, % 45.5 48.5
Mean±SD age, y 72.8±8.3 72.2±8.1
Age <70 y, % 31.0 34.1
Stroke, % 50.0 48.7
Chronic AF, % 71.6 72.5
Hypertension, % 55.8 54.6
Diabetes, % 20.3 15.4
Hyperlipidemia, % 19.5 18.9
Current smoking, % 18.4 20.5
Angina pectoris, %  7.6  8.6
Myocardial infarction, %  8.2  7.9
Mean±SD BP, mm Hg
Systolic 148.4±18.6 149.0±17.7
Diastolic 85.9±9.7 86.1±9.3
NYHA functional class, %
II 29.9 30.0
III  2.8  3.1
Mean±SD left atrial diameter, mm 43.0±7.9 43.7±8.5
LV fractional shortening ≤30%, % 49.8 51.8
CT brain scan, %
Appropriate lesion 33.5 34.1
Multiple infarct    8.2  6.8
Carotid stenosis ≥50%, % 10.8  9.5
Mean±SD interval between qualifying event and start of treatment, d 9.9±4.8 9.7±4.7
19/10/2017 Indobufen Versus Warfarin in the Secondary Prevention of Major Vascular Events in Nonrheumatic Atrial Fibrillation | Stroke
http://stroke.ahajournals.org/content/28/5/1015.full.print 6/15
View inline View popup
BP indicates blood pressure; NYHA, New York Heart Association; and LV, left ventricular. P>.05 for all comparisons
between the two treatment groups.
Follow-up
Nine patients (7 in the warfarin and 2 in the indobufen group) were lost to follow-up immediately after hospital discharge.
Adverse reactions led to drug withdrawal in 30 patients (21 in the warfarin and 9 in the indobufen group). An additional 51
patients (31 in the indobufen and 20 in the warfarin group) withdrew for other reasons (refusal to continue, onset of a
concomitant disease, or decision of the attending physician). Eight patients were temporarily withdrawn from treatment for 30
days or less. Patient compliance with the anticoagulant treatment was quite satisfactory: of the 2560 INR determinations,
83.5% fell within the prespeciﬁed range; 14.1% were below 2.0 and 2.4% above 3.5. In the indobufen group, 75% of the
patients received 200 mg BID and 25% received 100 mg BID.
Outcome Events
As shown in Table 2 , a total of 90 outcome events were recorded during follow-up, 49 in the patients randomized to
indobufen (10.6%; 95% CI, 7.7% to 13.5%) and 41 in those randomized to warfarin (9.0%; 95% CI, 6.3% to 11.8%).
Table 2.
Primary Outcome Events Recorded During Follow-up Analyzed According to Intention-to-Treat Principle
Intention-to-treat analysis showed that the proportion of patients developing a primary outcome event was not signiﬁcantly
diﬀerent between the two treatment groups: the observed diﬀerence was 0.016 (95% CI, −0.016 to 0.048), well below the 0.06
prespeciﬁed as the greatest tolerable diﬀerence. This is further conﬁrmed by the results of the χ  test used to test the
equivalence between the two treatments (χ =5.02; P<.025). The on-treatment analysis also failed to reveal any statistically
signiﬁcant diﬀerences between the two treatment groups, since the 79 on-treatment primary events were 44 in the indobufen-
treated patients (9.7%; 95% CI, 6.9% to 12.5%) and 35 in the warfarin-treated patients (7.9%; 95% CI, 5.3% to 10.5%). The
higher number of primary events in the intention-to-treat analysis was due to 8 cases of stroke (4 in each group) and 3 cases of
vascular death (1 on indobufen and 2 on warfarin).
The Figure  shows the Kaplan-Meier event-free survival curves for the two treatment groups (intention-to-treat). The
probability of remaining free of primary events at 12 months was 90.0% for the warfarin group and 88.0% for the indobufen
group (log-rank test: χ =0.52; P=.47).
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Figure 1.
Comparative survival curves for primary outcome events: vascular death, nonfatal stroke (including intracerebral bleeding),
nonfatal myocardial infarction, and nonfatal systemic or pulmonary embolism.
When the survival analysis was restricted to the patients on treatment, the 12-month cumulative event-free survival rate was
91.3% in the warfarin group and 89.2% in the indobufen group (P=.47).
A total of 41 fatal and nonfatal strokes occurred during follow-up, 23 in the indobufen group (5%) and 18 in the warfarin group
(4%) (P>.05); the type and severity of the events are reported in Table 3 . The nonsigniﬁcant diﬀerence between the two
treatments was due to an excess of minor ischemic strokes in the indobufen group, which was partially balanced by a slight
excess of cerebral bleeding in the warfarin group. The INR values measured when the event occurred were below 2.0 in 2 of
the 10 patients experiencing an ischemic stroke and were within the expected range in the 4 patients with hemorrhagic stroke.
The number of major or fatal strokes was 17 in the patients randomized to indobufen and 15 in those randomized to warfarin.
Table 3.
Cerebral Outcome Events in the Two Treatment Arms
A total of 7 nonvascular deaths were observed during the study: 4 in the indobufen group and 3 in the warfarin group.
To study the eﬀect of prognostic factors, all of the variables in Table 1  were inserted in a series of univariate Cox regression
analyses, and those that proved to be associated with an increased risk for stroke or recurrent vascular events (at a statistical
signiﬁcance level of P<.10) were included, together with treatment, in two multivariate models (one for stroke and one for
combined primary events). The results are given in Table 4 . Prior myocardial infarction and stroke as a qualifying event were
retained as independent risk factors for both recurrent stroke and combined vascular events, whereas female sex was a
predictor for recurrent stroke only. This multivariate analysis conﬁrmed the absence of any statistically signiﬁcant diﬀerence
between treatments even after we controlled for the inﬂuence of prognostic factors.
(
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Table 4.
Results of Multivariate Cox Regression Analysis Including Treatment and Risk Factors for Combined Primary Events and
Stroke Alone
Adverse Reactions
Fifty-four adverse reactions were recorded during follow-up: 21 in the patients treated with indobufen (mainly stomach pain,
nausea, and vomiting) and 33 in those treated with warfarin (mainly bleeding complications). These adverse reactions led to
treatment withdrawal in 9 patients on indobufen and 21 on warfarin. Twenty-six noncerebral bleeding episodes occurred during
the study: 3 in the indobufen group (0.6%) and 23 (5.1%) in the warfarin group, including all 4 cases of major gastrointestinal
bleeding (Table 5 ). This diﬀerence was statistically signiﬁcant (P<.01). When the bleeding complications occurred, the INR
values were out of the desired range in only 3 cases (two >3.5, one <2.0).
Table 5.
Noncerebral Bleeding Episodes Recorded in the Two Treatment Arms
Discussion
Patients with NRAF and a recent cerebrovascular ischemic episode are at high risk of subsequent major vascular events.  
The value of anticoagulation in reducing the risk of vascular recurrences in these patients has been established by a large
secondary prevention study (EAFT),  in which aspirin was found to be a signiﬁcantly less eﬀective therapeutic option. However,
because of the problems connected with oral anticoagulation, the search for a more convenient and safer eﬀective therapy is
still ongoing.
The recently published SPAF III trial,  which evaluated the combination of low-intensity ﬁxed-dose warfarin plus aspirin 325
mg/d, failed to ﬁnd a more convenient alternative to conventional anticoagulant treatment in NRAF patients at high risk of
stroke. However, for low-risk NRAF patients aged up to 75 years, aspirin represents a valid alternative to lifetime
anticoagulation, as shown in the SPAF I  and II  studies.
In the present study the frequency of the primary events observed in the patients treated with warfarin (9%), as well as the
incidence of recurrent stroke (4%), was similar to results of the EAFT study group in the patients receiving anticoagulation
treatment and not statistically diﬀerent from results in the indobufen group (10.6% and 5%, respectively). It should be
acknowledged, however, that the relatively small number of patients in our study does not allow us to exclude small though
clinically meaningful diﬀerences in eﬃcacy between indobufen and warfarin. The slightly higher rate (17.8% excess) of
outcome events in the indobufen-treated patients was mainly due to nondisabling ischemic strokes. The absence of any
statistical diﬀerence between treatments also remained after adjustment for the inﬂuence of prognostic factors, which
according to the multivariate analysis were female sex, stroke at admission, and a history of myocardial infarction.
The results observed with indobufen are consistent with the data obtained in a previously reported placebo-controlled trial
involving heart disease patients at increased embolic risk, in which indobufen markedly reduced the risk of all embolic events
by approximately two thirds. The favorable results obtained with indobufen in this setting may be due to its profound inhibition
of the cyclooxygenase activity of both constitutive and inducible prostaglandin endoperoxide synthases,   which are likely
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to be involved in sustaining enhanced thromboxane A  biosynthesis during acute cerebral ischemia.  Moreover, it should be
noted that approximately 20% of ischemic strokes in NRAF are considered to have an atherothrombotic mechanism,  against
which antiplatelet treatment has proved to be eﬀective.
In terms of safety, there was a statistically signiﬁcant between-treatment diﬀerence in the incidence of noncerebral
hemorrhagic events: 5.1% of the patients treated with warfarin (including four who required hospitalization) versus only 0.6% of
those treated with indobufen. However, the incidence of severe hemorrhagic events in our warfarin treatment group was lower
than that reported in other randomized studies,  probably because the close monitoring during follow-up favored patients
remaining within the optimal range.
Our study design does not allow us to indicate whether an early start of antithrombotic prophylaxis after a cerebral event (≤15
days) may provide more eﬀective protection against a recurrence of embolic events. However, because it is known that the risk
of recurrent brain ischemia  is higher during the ﬁrst few weeks, the fact that early treatment was not associated with any
increase in hemorrhagic risk in our study suggests that it is wise to start secondary prevention as early as possible. Moreover,
as a result of the relatively short follow-up, this study does not provide information on the long-term beneﬁt-risk balance of the
two treatments investigated. A further limitation of the study is related to its open nature, which does not allow us to rule out
the potential for nonblinded observer’s bias aﬀecting outcomes, although these were mostly fatal or disabling and were
independently classiﬁed by three members of the Steering Committee who were unaware of treatment allocation. However,
within these limitations we believe that the results of this study may be of value in better deﬁning the place of antiplatelet
agents in patients with NRAF, given the limited amount of trial data available.
Therefore, we conclude that SIFA may help the medical community in devising appropriate antithrombotic strategies for NRAF
patients for whom oral anticoagulants are contraindicated or do not represent a feasible approach to treatment.
Selected Abbreviations and Acronyms
AF = atrial ﬁbrillation
CI = conﬁdence interval
EAFT = European Atrial Fibrillation Trial
ECG = electrocardiogram, electrocardiographic
INR = international normalized ratio
NRAF = nonrheumatic atrial ﬁbrillation
SIFA = Studio Italiano Fibrillazione Atriale
SPAF = Stroke Prevention in Atrial Fibrillation
Appendix A1
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